CI Q3 2026 Earnings Analysis
Cigna raised FY2026 EPS guidance to ≥$30.60 on strong Evernorth and Cigna Healthcare performance while advancing Lead to 1 vision and Signature pharmacy model transition.
Key Metrics
Wichtigste Erkenntnisse
- Evernorth and Cigna Healthcare drove growth; company raised full-year 2026 EPS guidance to at least $30.60
- Specialty pharmacy and care services grew 15% YoY; Signature pharmacy model rolling out January 1, 2027
- Company targeting 10%-14% annual EPS growth long-term; $3B gross savings expected from Accelerate to 1 initiative by 2030
Anhören auf
Verfügbar in
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to listen to. I'm Alex...
...and I'm Jordan. Today we're digging into Cigna's third quarter 2026 results, and Alex, this is a company that's raising guidance while also telling investors "hey, 2027 is going to be a little weird."
Exactly, lots to unpack. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good to have that out of the way. So let's get into the numbers.
Cigna posted adjusted revenue of $73.8 billion for the quarter, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. And here's the headline: they raised full-year 2026 EPS guidance to at least $30.60.
That's a nice beat-and-raise story. And it's coming from two engines — Evernorth, their health services and pharmacy arm, and Cigna Healthcare, the traditional insurance side. Evernorth revenue grew 6% to $63.8 billion, with pretax earnings of $1.8 billion. Cigna Healthcare revenue was up 9% to $11.7 billion, pretax earnings of $1.2 billion.
And within Evernorth, the real star was Specialty and Care Services — that's Accredo, their specialty pharmacy, and CuraScript, their distribution business. Pretax earnings there grew 15% year-over-year to $1.1 billion.
That's being driven by biosimilars and specialty generics hitting their stride. Generic Revlimid, a big oncology drug, is now at about 90% penetration. Biosimilar Humira and Stelara are seeing strong adoption too, especially with Cigna offering zero-dollar out-of-pocket options for patients.
It's a good reminder that the "boring" parts of healthcare — drug substitution, supply chain efficiency — can actually be huge profit drivers.
Right, and on the Cigna Healthcare side, their medical care ratio — basically how much premium revenue goes out the door in claims — came in at 85%, right in line with expectations. Medical customers grew 2% year-to-date to 18.5 million, with particularly strong growth in their Select segment, which serves smaller employers.
Now let's talk strategy, because CEO Brian Evanko spent a lot of time on something called "Lead to 1." It's their big vision going forward.
Lead to 1 is essentially about personalization at scale using data and AI. The stat that jumped out at me: 8% of patients account for 55% of total healthcare spending. So the whole strategy is built around identifying those complex, high-cost patients earlier and intervening before costs spiral.
They launched something called HealthSense in September — a tool that connects a patient's health needs, benefits, pharmacy coverage, and claims history so clinical teams get the full picture. It's starting with oncology.
And they gave some compelling numbers around this — an integrated cancer patient journey can save $28,000 per person per year. That's not a typo, that's the scale of savings they're talking about for complex care coordination.
The other big strategic story is the "Signature" model — this is Cigna's attempt to reinvent pharmacy benefits. Instead of the traditional rebate-driven system, it's a fee-based, transparent model.
Which matters because, let's be honest, PBMs have taken a lot of regulatory and public heat for opacity. Signature is designed to guarantee patients the lowest available out-of-pocket cost on prescriptions — they're calling it "Price Assure," and it's already saving about 30% on high-cost branded drugs for the roughly 10% of clients using it now.
The rollout plan is phased — design phase done, build phase underway with manufacturers and pharmacy networks, and adoption kicks off January 1, 2027 for Cigna's own fully-insured book, with broader Evernorth client adoption expected in 2028.
Now here's where it gets interesting for investors — the Q&A session was really about 2027 being a transition year. Management flagged three headwinds: compression in industry-wide drug rebate pools, lower employer coverage of GLP-1 weight-loss drugs, a thinner pipeline of new biosimilar launches, and — the big one — Cigna's planned exit from the ACA exchange market.
That exchange exit alone is about a $200 million headwind, which is why they're setting investors' expectations around a 2027 "run-rate" EPS base of roughly $30, even though 2026 is finishing north of $30.60.
It's a classic "clear the deck" move — take the lower-margin, less strategic business off the table so the growth story going forward is cleaner. They're still committing to at least 10% EPS growth in 2027 off that $30 base, and reaffirming their long-term target of 10% to 14% average annual EPS growth through 2030, with an EPS target of at least $45 by then.
One analyst asked a great question about recapturing that $200 million ACA headwind in 2028 — management said they're actively working to shed the stranded overhead costs that linger after an exit like this.
There was also a nice exchange about their "Accelerate to 1" initiative — a cost and modernization program targeting $3 billion in gross run-rate savings by 2030. Importantly, they said 70-80% of that comes from automation and talent effectiveness, the rest from vendor and supplier optimization. Not all of it falls to the bottom line — some gets reinvested into growth.
And stop-loss insurance margins — that's a business where employers insure against catastrophic claims — are recovering nicely after some pricing discipline. That's actually one of the tailwinds heading into 2027, alongside a strong 2027 selling season with retention in the high 90s.
So what's the takeaway for investors here, Alex?
I'd say it's a company executing well in the near term — beat-and-raise quarter, disciplined pricing, strong specialty pharmacy growth — while being very transparent that 2027 is a reset year. The ACA exit and PBM rebate pressures create real headwinds, but management is laying out multiple levers — Signature, specialty expansion, cost savings — to get back to double-digit growth.
And before we wrap, our standard reminder: everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Looking ahead, the fourth quarter call will be the big one — that's when Cigna lays out full 2027 guidance in detail, including the specific contributions from each segment.
Definitely a call to circle on your calendar if you're following this name.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time.
See you then!